PHARMACOKINETICS OF INFLIXIMAB (Anti‐TNF∞) IN CHILDREN WITH CROHN'S DISEASE: A MULTICENTER TRIAL
Colleen Hadigan(Harvard University), Harland S. Winter(Harvard University), George D. Ferry(Baylor College of Medicine), Barbara S. Kirschner(Comer Children's Hospital), E Vasiliauskis(Children's Hospital of Philadelphia), Kimberly L. DeWoody(Children's Hospital of Philadelphia), Christian Braegger(University Children's Hospital Zurich), Robert B. Livingston(Children's Hospital of Philadelphia), Carrie Wagner(Children's Hospital of Philadelphia), Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), M. Sinaasappel(Cystic Fibrosis Foundation), Robert N. Baldassano(Children's Hospital of Philadelphia)
Journal of Pediatric Gastroenterology and Nutrition
October 1, 1999
Cited by 1
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
|Journal of Pediatric Gastroenterology and Nutrition|2013|1.4k